Survodutide
A weight loss injection being developed specifically for both obesity and fatty liver disease (MASH). It reduces appetite through one pathway while simultaneously telling your liver to burn its stored fat through another. This dual approach tackles the root cause (eating too much) and the downstream damage (fat build-up in the liver) at the same time. Still in clinical trials.
Dosage
Up to 6 mg subcutaneous once weekly
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (weekly)
Shop Research-Grade Peptides
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Liver Fat Reduction
Specifically developed for MASH — strong hepatic triglyceride reduction in trials.
Weight Loss
Substantial body weight reduction through combined appetite and metabolic mechanisms.
Energy Expenditure
Glucagon signaling increases thermogenesis and basal metabolic rate.
Mechanism of Action
Survodutide activates both GLP-1 and glucagon receptors with a carefully calibrated ratio of agonist activity at each target. The GLP-1 receptor engagement provides the established metabolic benefits of the incretin pathway — centrally mediated appetite suppression, glucose-dependent insulinotropic effects, and delayed gastric emptying — creating a foundation of weight loss and glycemic improvement.
The glucagon receptor component is particularly relevant to survodutide's development focus on MASH (metabolic dysfunction-associated steatohepatitis). Glucagon receptor activation in hepatocytes upregulates mitochondrial beta-oxidation of fatty acids, increases ketone body production, and stimulates amino acid catabolism. This hepatic metabolic shift directly addresses the pathological fat accumulation that defines MASH, reducing intrahepatic triglyceride content by mobilizing stored lipids for energy production rather than continued storage.
Beyond the liver, glucagon signaling increases whole-body energy expenditure through multiple mechanisms: enhanced thermogenesis in brown adipose tissue, increased futile cycling in metabolic pathways, and elevated basal metabolic rate. In clinical trials for MASH, survodutide has demonstrated significant reductions in liver fat content alongside substantial body weight loss. The dual mechanism addresses both the upstream cause (excess caloric intake) and the downstream pathology (hepatic steatosis and inflammation) of metabolic liver disease simultaneously.
Regulatory Status
Not FDA approved. Phase 3 trials ongoing for obesity and MASH. Boehringer Ingelheim/Zealand Pharma.
Risks & Safety
Common
nausea, diarrhea, vomiting, constipation, reduced appetite.
Serious
slightly elevated heart rate, changes in liver enzymes, inflammation of the pancreas, gallstones.
Rare
thyroid concerns (based on similar drugs in animals), severe allergic reactions.
Compare Survodutide With
Research Papers
30Published: January 29, 2026
AI Summary
Adding glucagon receptor activation to GLP-1 drugs may boost weight loss by increasing energy use. Survodutide and other dual or triple agonists are being developed to improve on current incretin therapies.
Published: January 11, 2026
AI Summary
A network meta-analysis compared glucagon receptor agonists like survodutide with resmetirom for fatty liver disease. The review evaluates their relative efficacy and safety.
Published: November 22, 2025
AI Summary
New diabetes and obesity drugs like survodutide and retatrutide may join existing kidney-protective treatments. The review summarizes trials and future strategies for diabetes and kidney disease.
Published: November 23, 2025
AI Summary
GLP-1 drugs have transformed obesity treatment and may help in fatty liver, heart disease, and other conditions. The review outlines their promise and remaining hurdles.
Published: February 10, 2026
AI Summary
The paper describes the baseline characteristics of participants in SYNCHRONIZE-2, a phase 3 trial of survodutide for obesity in people with type 2 diabetes.
Published: January 3, 2026
AI Summary
The paper reports baseline characteristics of participants in SYNCHRONIZE-1, a phase 3 trial of survodutide for obesity in adults without type 2 diabetes.
Published: October 6, 2025
AI Summary
Glucagon co-agonists like survodutide and mazdutide have shown strong weight loss and blood sugar improvements. The review covers new GLP-1-based drugs in development.
Published: December 29, 2025
AI Summary
Glucagon affects fat burning and energy use, and dual agonists like survodutide are being tested for obesity and fatty liver. Phase 3 trials will clarify their safety and efficacy.
Published: September 17, 2025
AI Summary
Survodutide produced up to 18.7% weight loss and improved liver fat and fibrosis in phase 2 trials, outperforming semaglutide for weight. An ongoing cardiovascular outcomes trial will test whether these benefits reduce heart events.
Published: November 25, 2025
AI Summary
New obesity drugs can achieve 15–25% weight loss. Survodutide and other GLP-1/glucagon combinations are expected to reach similar weight loss to tirzepatide and retatrutide.
Published: September 20, 2025
AI Summary
Resmetirom and semaglutide are approved or under review for fatty liver disease. The review discusses their safety profiles and how to choose between current and emerging options.
Published: July 27, 2025
AI Summary
Dual GLP-1/glucagon agonists like survodutide outperform GLP-1-only drugs for weight and blood sugar, with early signs of heart and kidney benefits. The review examines their role across cardiometabolic disease.
Published: July 23, 2025
AI Summary
Glucagon-based multi-agonists like survodutide have shown strong weight loss in trials and may become important obesity treatments. Cost, access, and long-term safety remain key considerations.
Published: June 27, 2025
AI Summary
A meta-analysis of three trials found survodutide reduced body weight by about 8–9% and HbA1c by about 0.9% versus placebo. Gastrointestinal side effects were common and led to more treatment stops.
Published: November 19, 2025
AI Summary
A Bayesian network meta-analysis compared GLP-1 agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity.
Published: September 4, 2025
AI Summary
A long-acting PYY-like drug enhanced weight loss when combined with survodutide in preclinical studies. The combination may offer stronger anti-obesity effects than either drug alone.
Published: May 4, 2025
AI Summary
Abstract too short to summarize.
Published: March 31, 2025
AI Summary
A systematic review and meta-analysis evaluated the efficacy and safety of survodutide for obesity.
Published: September 15, 2025
AI Summary
A systematic review and meta-analysis assessed the effects of GLP-1-based therapies on fatty liver disease and steatohepatitis.
Published: June 12, 2025
AI Summary
Incretin mimetics and related hormones are emerging as disease-modifying options for fatty liver. The review covers GLP-1 and dual/triple agonists in this setting.
Published: May 10, 2025
AI Summary
Incretin therapies like survodutide are expanding beyond glucose and weight to liver, heart, and kidney benefits. The review covers developments from 2023 to early 2025.
Published: March 16, 2025
AI Summary
GLP-1 and dual agonists may benefit fatty liver beyond their effects on weight and blood sugar. The review discusses these benefits for gastroenterologists.
Published: January 21, 2025
AI Summary
Survodutide is in phase 3 obesity trials. The systematic review summarizes the obesity drug pipeline and the most promising emerging options.
Published: April 15, 2025
AI Summary
The study explored whether sex and baseline BMI affected the efficacy and safety of survodutide in people with a BMI of 27 or higher.
Published: December 27, 2024
AI Summary
Survodutide and tirzepatide have shown promising results for fatty liver disease, with higher rates of disease resolution and fibrosis improvement than GLP-1-only drugs. Gastrointestinal side effects remain a concern.
Published: September 3, 2024
AI Summary
Survodutide, mazdutide, and pemvidutide have shown significant weight loss in trials. The review summarizes approved and emerging hormone-based obesity medications.
Published: December 16, 2024
AI Summary
Survodutide targets both glucagon and GLP-1 receptors and may address liver and systemic metabolic dysfunction in obesity and fatty liver disease.
Published: February 24, 2025
AI Summary
Abstract too short to summarize.
Published: January 3, 2025
AI Summary
The paper describes the design and rationale of two phase 3 trials of survodutide for obesity with or without type 2 diabetes.
Published: December 29, 2024
AI Summary
Weight loss from drugs often includes loss of muscle and bone. New compounds that block muscle breakdown may help preserve lean mass when combined with incretin-based obesity treatments.
Frequently Asked Questions
What is Survodutide?
A weight loss injection being developed specifically for both obesity and fatty liver disease (MASH). It reduces appetite through one pathway while simultaneously telling your liver to burn its stored fat through another. This dual approach tackles the root cause (eating too much) and the downstream damage (fat build-up in the liver) at the same time. Still in clinical trials.
What is Survodutide used for?
A weight loss injection being developed specifically for both obesity and fatty liver disease (MASH). It reduces appetite through one pathway while simultaneously telling your liver to burn its stored fat through another. This dual approach tackles the root cause (eating too much) and the downstream damage (fat build-up in the liver) at the same time. Still in clinical trials.
What is the dosage for Survodutide?
Clinical trials: up to 6 mg subcutaneous once weekly. Dose escalation required over initial weeks starting at lower doses. Optimal dosing still being established in Phase 3.
What are the side effects of Survodutide?
Common: nausea, diarrhea, vomiting, constipation, reduced appetite. Serious: slightly elevated heart rate, changes in liver enzymes, inflammation of the pancreas, gallstones. Rare: thyroid concerns (based on similar drugs in animals), severe allergic reactions.
How does Survodutide work?
Survodutide activates both GLP-1 and glucagon receptors with a carefully calibrated ratio of agonist activity at each target. The GLP-1 receptor engagement provides the established metabolic benefits of the incretin pathway — centrally mediated appetite suppression, glucose-dependent insulinotropic effects, and delayed gastric emptying — creating a foundation of weight loss and glycemic improvement. The glucagon receptor component is particularly relevant to survodutide's development focus on MASH (metabolic dysfunction-associated steatohepatitis). Glucagon receptor activation in hepatocytes upregulates mitochondrial beta-oxidation of fatty acids, increases ketone body production, and stimulates amino acid catabolism. This hepatic metabolic shift directly addresses the pathological fat accumulation that defines MASH, reducing intrahepatic triglyceride content by mobilizing stored lipids for energy production rather than continued storage. Beyond the liver, glucagon signaling increases whole-body energy expenditure through multiple mechanisms: enhanced thermogenesis in brown adipose tissue, increased futile cycling in metabolic pathways, and elevated basal metabolic rate. In clinical trials for MASH, survodutide has demonstrated significant reductions in liver fat content alongside substantial body weight loss. The dual mechanism addresses both the upstream cause (excess caloric intake) and the downstream pathology (hepatic steatosis and inflammation) of metabolic liver disease simultaneously.
How is Survodutide administered?
Survodutide is administered via subcutaneous injection (weekly).
What is the half-life of Survodutide?
The half-life of Survodutide is 144 hours (6 days).
Is Survodutide legal?
Not FDA approved. Phase 3 trials ongoing for obesity and MASH. Boehringer Ingelheim/Zealand Pharma.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
Cagrilintide
A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.